

Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Growth 2023-2029

<https://marketpublishers.com/r/G55C29A9FD20EN.html>

Date: November 2023

Pages: 131

Price: US\$ 3,660.00 (Single User License)

ID: G55C29A9FD20EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

According to our LPI (LP Information) latest study, the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market size was valued at US\$ 97.8 million in 2022. With growing demand in downstream market, the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment is forecast to a readjusted size of US\$ 208.4 million by 2029 with a CAGR of 11.4% during review period.

The research report highlights the growth potential of the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market.

Paroxysmal nocturnal hemoglobinuria (PNH) is a non-malignant clonal disease caused by acquired somatic PIG-A gene (phosphatidylinositol glycan complementation group A) mutations in one or several hematopoietic stem cells. Disease, PIG-A mutation causes abnormal synthesis of glycosyl phosphatidylinositol (GPI), resulting in the loss of a group of membrane proteins anchored to the cell membrane by GPI, including CD16, CD55, CD59, etc., which are mainly clinically. It manifests as chronic intravascular hemolysis, hematopoietic failure and recurrent thrombosis.

The paroxysmal nocturnal hemoglobinuria (PNH) treatment market is a growing area focused on developing innovative drugs and treatments to improve the quality of life of patients with PNH. The market covers various treatment options, including monoclonal antibody therapies, immunosuppressive drugs, and hematopoietic stem cell transplantation, aimed at alleviating symptoms, controlling hemolysis, and improving blood abnormalities in PNH patients, thus providing better clinical outcomes. As scientific research continues to advance and medical technology continues to improve, the PNH treatment market is expected to continue to expand, providing patients with more treatment options and the opportunity to improve survival rates.

Key Features:

The report on Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market reflects various aspects and provide valuable insights into the industry.

Market Size and Growth: The research report provide an overview of the current size and growth of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market. It may include historical data, market segmentation by Type (e.g., Monoclonal Antibodies Therapy, Immunosuppressive Drugs), and regional breakdowns.

Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.

Competitive Landscape: The research report provides analysis of the competitive landscape within the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.

Technological Developments: The research report can delve into the latest technological developments in the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment industry. This include advancements in Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment technology, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment new entrants, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment new investment, and other innovations that are shaping the future of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment.

Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market. It includes factors influencing customer ' purchasing decisions, preferences for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment product.

Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market. The report also evaluates the effectiveness of these policies in driving market growth.

Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market.

Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.

Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market.

Market Segmentation:

Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.

Segmentation by type

Monoclonal Antibodies Therapy

Immunosuppressive Drugs

Hematopoietic Stem Cell Transplantation

Segmentation by application

Hospital

Clinic

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Amoun Pharmaceuticals

EIPICO

Minapharm Pharmaceuticals

Pharco Pharmaceuticals

Alexion Pharmaceuticals

Alnylam Pharmaceuticals

Akari Therapeutics

Amgen

CSL Behring

Bioverativ

F. Hoffmann-La Roche Ltd

Novartis AG

Amgen Inc

Teva Pharmaceutical

Abbott

Key Questions Addressed in this Report

What is the 10-year outlook for the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market?

What factors are driving Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market opportunities vary by end market size?

How does Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment break out type, application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Annual Sales 2018-2029
 - 2.1.2 World Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Geographic Region, 2018, 2022 & 2029
 - 2.1.3 World Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Country/Region, 2018, 2022 & 2029
- 2.2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Segment by Type
 - 2.2.1 Monoclonal Antibodies Therapy
 - 2.2.2 Immunosuppressive Drugs
 - 2.2.3 Hematopoietic Stem Cell Transplantation
- 2.3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Type
 - 2.3.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Type (2018-2023)
 - 2.3.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue and Market Share by Type (2018-2023)
 - 2.3.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sale Price by Type (2018-2023)
- 2.4 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Segment by Application
 - 2.4.1 Hospital
 - 2.4.2 Clinic
 - 2.4.3 Other
- 2.5 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Application
 - 2.5.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sale Market

Share by Application (2018-2023)

2.5.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue and Market Share by Application (2018-2023)

2.5.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sale Price by Application (2018-2023)

3 GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT BY COMPANY

3.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Breakdown Data by Company

3.1.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Annual Sales by Company (2018-2023)

3.1.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Company (2018-2023)

3.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Annual Revenue by Company (2018-2023)

3.2.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Company (2018-2023)

3.2.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Company (2018-2023)

3.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sale Price by Company

3.4 Key Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Location Distribution

3.4.2 Players Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT BY GEOGRAPHIC REGION

4.1 World Historic Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size

by Geographic Region (2018-2023)

4.1.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Annual Sales by Geographic Region (2018-2023)

4.1.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Annual Revenue by Geographic Region (2018-2023)

4.2 World Historic Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size by Country/Region (2018-2023)

4.2.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Annual Sales by Country/Region (2018-2023)

4.2.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Annual Revenue by Country/Region (2018-2023)

4.3 Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Growth

4.4 APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Growth

4.5 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Growth

4.6 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Growth

5 AMERICAS

5.1 Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Country

5.1.1 Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Country (2018-2023)

5.1.2 Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Country (2018-2023)

5.2 Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Type

5.3 Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Region

6.1.1 APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Region (2018-2023)

6.1.2 APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Region (2018-2023)

- 6.2 APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Type
- 6.3 APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Application
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

7 EUROPE

- 7.1 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Country
 - 7.1.1 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Country (2018-2023)
 - 7.1.2 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Country (2018-2023)
- 7.2 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Type
- 7.3 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Country
 - 8.1.1 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Country (2018-2023)
 - 8.1.2 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Country (2018-2023)
- 8.2 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Type
- 8.3 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Application
- 8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment

10.3 Manufacturing Process Analysis of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment

10.4 Industry Chain Structure of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Distributors

11.3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Customer

12 WORLD FORECAST REVIEW FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT BY GEOGRAPHIC REGION

12.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size Forecast by Region

12.1.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Forecast by Region (2024-2029)

12.1.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Annual Revenue Forecast by Region (2024-2029)

12.2 Americas Forecast by Country

- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Forecast by Type
- 12.7 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Forecast by Application

13 KEY PLAYERS ANALYSIS

13.1 Amoun Pharmaceuticals

- 13.1.1 Amoun Pharmaceuticals Company Information
- 13.1.2 Amoun Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
- 13.1.3 Amoun Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.1.4 Amoun Pharmaceuticals Main Business Overview
- 13.1.5 Amoun Pharmaceuticals Latest Developments

13.2 EIPICO

- 13.2.1 EIPICO Company Information
- 13.2.2 EIPICO Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
- 13.2.3 EIPICO Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.2.4 EIPICO Main Business Overview
- 13.2.5 EIPICO Latest Developments

13.3 Minapharm Pharmaceuticals

- 13.3.1 Minapharm Pharmaceuticals Company Information
- 13.3.2 Minapharm Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
- 13.3.3 Minapharm Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.3.4 Minapharm Pharmaceuticals Main Business Overview
- 13.3.5 Minapharm Pharmaceuticals Latest Developments

13.4 Pharco Pharmaceuticals

- 13.4.1 Pharco Pharmaceuticals Company Information
- 13.4.2 Pharco Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
- 13.4.3 Pharco Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)

- 13.4.4 Pharco Pharmaceuticals Main Business Overview
- 13.4.5 Pharco Pharmaceuticals Latest Developments
- 13.5 Alexion Pharmaceuticals
 - 13.5.1 Alexion Pharmaceuticals Company Information
 - 13.5.2 Alexion Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
 - 13.5.3 Alexion Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.5.4 Alexion Pharmaceuticals Main Business Overview
 - 13.5.5 Alexion Pharmaceuticals Latest Developments
- 13.6 Alnylam Pharmaceuticals
 - 13.6.1 Alnylam Pharmaceuticals Company Information
 - 13.6.2 Alnylam Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
 - 13.6.3 Alnylam Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.6.4 Alnylam Pharmaceuticals Main Business Overview
 - 13.6.5 Alnylam Pharmaceuticals Latest Developments
- 13.7 Akari Therapeutics
 - 13.7.1 Akari Therapeutics Company Information
 - 13.7.2 Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
 - 13.7.3 Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.7.4 Akari Therapeutics Main Business Overview
 - 13.7.5 Akari Therapeutics Latest Developments
- 13.8 Amgen
 - 13.8.1 Amgen Company Information
 - 13.8.2 Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
 - 13.8.3 Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.8.4 Amgen Main Business Overview
 - 13.8.5 Amgen Latest Developments
- 13.9 CSL Behring
 - 13.9.1 CSL Behring Company Information
 - 13.9.2 CSL Behring Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
 - 13.9.3 CSL Behring Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales,

Revenue, Price and Gross Margin (2018-2023)

13.9.4 CSL Behring Main Business Overview

13.9.5 CSL Behring Latest Developments

13.10 Bioverativ

13.10.1 Bioverativ Company Information

13.10.2 Bioverativ Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications

13.10.3 Bioverativ Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)

13.10.4 Bioverativ Main Business Overview

13.10.5 Bioverativ Latest Developments

13.11 F. Hoffmann-La Roche Ltd

13.11.1 F. Hoffmann-La Roche Ltd Company Information

13.11.2 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications

13.11.3 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)

13.11.4 F. Hoffmann-La Roche Ltd Main Business Overview

13.11.5 F. Hoffmann-La Roche Ltd Latest Developments

13.12 Novartis AG

13.12.1 Novartis AG Company Information

13.12.2 Novartis AG Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications

13.12.3 Novartis AG Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)

13.12.4 Novartis AG Main Business Overview

13.12.5 Novartis AG Latest Developments

13.13 Amgen Inc

13.13.1 Amgen Inc Company Information

13.13.2 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications

13.13.3 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)

13.13.4 Amgen Inc Main Business Overview

13.13.5 Amgen Inc Latest Developments

13.14 Teva Pharmaceutical

13.14.1 Teva Pharmaceutical Company Information

13.14.2 Teva Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications

13.14.3 Teva Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)

13.14.4 Teva Pharmaceutical Main Business Overview

13.14.5 Teva Pharmaceutical Latest Developments

13.15 Abbott

13.15.1 Abbott Company Information

13.15.2 Abbott Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications

13.15.3 Abbott Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)

13.15.4 Abbott Main Business Overview

13.15.5 Abbott Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

- Table 1. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & (\$ millions)
- Table 2. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & (\$ millions)
- Table 3. Major Players of Monoclonal Antibodies Therapy
- Table 4. Major Players of Immunosuppressive Drugs
- Table 5. Major Players of Hematopoietic Stem Cell Transplantation
- Table 6. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Type (2018-2023) & (K Units)
- Table 7. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Type (2018-2023)
- Table 8. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Type (2018-2023) & (\$ million)
- Table 9. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Type (2018-2023)
- Table 10. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sale Price by Type (2018-2023) & (US\$/Unit)
- Table 11. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Application (2018-2023) & (K Units)
- Table 12. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Application (2018-2023)
- Table 13. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Application (2018-2023)
- Table 14. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Application (2018-2023)
- Table 15. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sale Price by Application (2018-2023) & (US\$/Unit)
- Table 16. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Company (2018-2023) & (K Units)
- Table 17. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Company (2018-2023)
- Table 18. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Company (2018-2023) (\$ Millions)
- Table 19. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Company (2018-2023)

Table 20. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sale Price by Company (2018-2023) & (US\$/Unit)

Table 21. Key Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Producing Area Distribution and Sales Area

Table 22. Players Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Products Offered

Table 23. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

Table 24. New Products and Potential Entrants

Table 25. Mergers & Acquisitions, Expansion

Table 26. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Geographic Region (2018-2023) & (K Units)

Table 27. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share Geographic Region (2018-2023)

Table 28. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Geographic Region (2018-2023) & (\$ millions)

Table 29. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Geographic Region (2018-2023)

Table 30. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Country/Region (2018-2023) & (K Units)

Table 31. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Country/Region (2018-2023)

Table 32. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Country/Region (2018-2023) & (\$ millions)

Table 33. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Country/Region (2018-2023)

Table 34. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Country (2018-2023) & (K Units)

Table 35. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Country (2018-2023)

Table 36. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Country (2018-2023) & (\$ Millions)

Table 37. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Country (2018-2023)

Table 38. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Type (2018-2023) & (K Units)

Table 39. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Application (2018-2023) & (K Units)

Table 40. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by

Region (2018-2023) & (K Units)

Table 41. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Region (2018-2023)

Table 42. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Region (2018-2023) & (\$ Millions)

Table 43. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Region (2018-2023)

Table 44. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Type (2018-2023) & (K Units)

Table 45. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Application (2018-2023) & (K Units)

Table 46. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Country (2018-2023) & (K Units)

Table 47. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Country (2018-2023)

Table 48. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Country (2018-2023) & (\$ Millions)

Table 49. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Country (2018-2023)

Table 50. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Type (2018-2023) & (K Units)

Table 51. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Application (2018-2023) & (K Units)

Table 52. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Country (2018-2023) & (K Units)

Table 53. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Country (2018-2023)

Table 54. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Country (2018-2023) & (\$ Millions)

Table 55. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Country (2018-2023)

Table 56. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Type (2018-2023) & (K Units)

Table 57. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Application (2018-2023) & (K Units)

Table 58. Key Market Drivers & Growth Opportunities of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment

Table 59. Key Market Challenges & Risks of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment

Table 60. Key Industry Trends of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment

Table 61. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Raw Material

Table 62. Key Suppliers of Raw Materials

Table 63. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Distributors List

Table 64. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Customer List

Table 65. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Forecast by Region (2024-2029) & (K Units)

Table 66. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 67. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Forecast by Country (2024-2029) & (K Units)

Table 68. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 69. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Forecast by Region (2024-2029) & (K Units)

Table 70. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 71. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Forecast by Country (2024-2029) & (K Units)

Table 72. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 73. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Forecast by Country (2024-2029) & (K Units)

Table 74. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 75. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Forecast by Type (2024-2029) & (K Units)

Table 76. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Forecast by Type (2024-2029) & (\$ Millions)

Table 77. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Forecast by Application (2024-2029) & (K Units)

Table 78. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Forecast by Application (2024-2029) & (\$ Millions)

Table 79. Amoun Pharmaceuticals Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors

Table 80. Amoun Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications

Table 81. Amoun Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH)

Treatment Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 82. Amoun Pharmaceuticals Main Business

Table 83. Amoun Pharmaceuticals Latest Developments

Table 84. EIPICO Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors

Table 85. EIPICO Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications

Table 86. EIPICO Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 87. EIPICO Main Business

Table 88. EIPICO Latest Developments

Table 89. Minapharm Pharmaceuticals Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors

Table 90. Minapharm Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications

Table 91. Minapharm Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 92. Minapharm Pharmaceuticals Main Business

Table 93. Minapharm Pharmaceuticals Latest Developments

Table 94. Pharco Pharmaceuticals Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors

Table 95. Pharco Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications

Table 96. Pharco Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 97. Pharco Pharmaceuticals Main Business

Table 98. Pharco Pharmaceuticals Latest Developments

Table 99. Alexion Pharmaceuticals Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors

Table 100. Alexion Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications

Table 101. Alexion Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 102. Alexion Pharmaceuticals Main Business

Table 103. Alexion Pharmaceuticals Latest Developments

- Table 104. Alnylam Pharmaceuticals Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors
- Table 105. Alnylam Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
- Table 106. Alnylam Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
- Table 107. Alnylam Pharmaceuticals Main Business
- Table 108. Alnylam Pharmaceuticals Latest Developments
- Table 109. Akari Therapeutics Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors
- Table 110. Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
- Table 111. Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
- Table 112. Akari Therapeutics Main Business
- Table 113. Akari Therapeutics Latest Developments
- Table 114. Amgen Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors
- Table 115. Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
- Table 116. Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
- Table 117. Amgen Main Business
- Table 118. Amgen Latest Developments
- Table 119. CSL Behring Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors
- Table 120. CSL Behring Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
- Table 121. CSL Behring Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
- Table 122. CSL Behring Main Business
- Table 123. CSL Behring Latest Developments
- Table 124. Bioverativ Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors
- Table 125. Bioverativ Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
- Table 126. Bioverativ Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 127. Bioverativ Main Business

Table 128. Bioverativ Latest Developments

Table 129. F. Hoffmann-La Roche Ltd Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors

Table 130. F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications

Table 131. F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 132. F. Hoffmann-La Roche Ltd Main Business

Table 133. F. Hoffmann-La Roche Ltd Latest Developments

Table 134. Novartis AG Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors

Table 135. Novartis AG Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications

Table 136. Novartis AG Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 137. Novartis AG Main Business

Table 138. Novartis AG Latest Developments

Table 139. Amgen Inc Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors

Table 140. Amgen Inc Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications

Table 141. Amgen Inc Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 142. Amgen Inc Main Business

Table 143. Amgen Inc Latest Developments

Table 144. Teva Pharmaceutical Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors

Table 145. Teva Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications

Table 146. Teva Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 147. Teva Pharmaceutical Main Business

Table 148. Teva Pharmaceutical Latest Developments

Table 149. Abbott Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors

Table 150. Abbott Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product

Portfolios and Specifications

Table 151. Abbott Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 152. Abbott Main Business

Table 153. Abbott Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment
- Figure 2. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Growth Rate 2018-2029 (K Units)
- Figure 7. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth Rate 2018-2029 (\$ Millions)
- Figure 8. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Region (2018, 2022 & 2029) & (\$ Millions)
- Figure 9. Product Picture of Monoclonal Antibodies Therapy
- Figure 10. Product Picture of Immunosuppressive Drugs
- Figure 11. Product Picture of Hematopoietic Stem Cell Transplantation
- Figure 12. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Type in 2022
- Figure 13. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Type (2018-2023)
- Figure 14. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Consumed in Hospital
- Figure 15. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market: Hospital (2018-2023) & (K Units)
- Figure 16. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Consumed in Clinic
- Figure 17. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market: Clinic (2018-2023) & (K Units)
- Figure 18. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Consumed in Other
- Figure 19. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market: Other (2018-2023) & (K Units)
- Figure 20. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Application (2022)
- Figure 21. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Application in 2022
- Figure 22. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market by Company in 2022 (K Units)

Figure 23. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Company in 2022

Figure 24. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market by Company in 2022 (\$ Million)

Figure 25. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Company in 2022

Figure 26. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Geographic Region (2018-2023)

Figure 27. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Geographic Region in 2022

Figure 28. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales 2018-2023 (K Units)

Figure 29. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue 2018-2023 (\$ Millions)

Figure 30. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales 2018-2023 (K Units)

Figure 31. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue 2018-2023 (\$ Millions)

Figure 32. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales 2018-2023 (K Units)

Figure 33. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue 2018-2023 (\$ Millions)

Figure 34. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales 2018-2023 (K Units)

Figure 35. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue 2018-2023 (\$ Millions)

Figure 36. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Country in 2022

Figure 37. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Country in 2022

Figure 38. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Type (2018-2023)

Figure 39. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Application (2018-2023)

Figure 40. United States Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 41. Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 42. Mexico Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue

Growth 2018-2023 (\$ Millions)

Figure 43. Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue

Growth 2018-2023 (\$ Millions)

Figure 44. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Region in 2022

Figure 45. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Regions in 2022

Figure 46. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Type (2018-2023)

Figure 47. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Application (2018-2023)

Figure 48. China Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 49. Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 50. South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 51. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 52. India Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 53. Australia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 54. China Taiwan Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 55. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Country in 2022

Figure 56. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Country in 2022

Figure 57. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Type (2018-2023)

Figure 58. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Application (2018-2023)

Figure 59. Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 60. France Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 61. UK Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 62. Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 63. Russia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 64. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Country in 2022

Figure 65. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Country in 2022

Figure 66. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Type (2018-2023)

Figure 67. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Application (2018-2023)

Figure 68. Egypt Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 69. South Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 70. Israel Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 71. Turkey Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 72. GCC Country Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 73. Manufacturing Cost Structure Analysis of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment in 2022

Figure 74. Manufacturing Process Analysis of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment

Figure 75. Industry Chain Structure of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment

Figure 76. Channels of Distribution

Figure 77. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Forecast by Region (2024-2029)

Figure 78. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share Forecast by Region (2024-2029)

Figure 79. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share Forecast by Type (2024-2029)

Figure 80. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share Forecast by Type (2024-2029)

Figure 81. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share Forecast by Application (2024-2029)

Figure 82. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share Forecast by Application (2024-2029)

I would like to order

Product name: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Growth 2023-2029

Product link: <https://marketpublishers.com/r/G55C29A9FD20EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G55C29A9FD20EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

